Report cover image

Global Rotavirus Infections Drug Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 92 Pages
SKU # APRC20548686

Description

Summary

According to APO Research, The global Rotavirus Infections Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Rotavirus Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rotavirus Infections Drug.
The Rotavirus Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rotavirus Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Rotavirus Infections Drug Segment by Company

Wuhan Institute of Biological Products Co Ltd
Beijing Minhai Biotechnology Co Ltd
UMN Pharma Inc
Serum Institute of India Ltd
Nanotherapeutics Inc
Medicago Inc
Curevac AG
Biological E Ltd
Bharat Biotech International Ltd
Rotavirus Infections Drug Segment by Type

UMN-2001
RV-625
RV-3BB
Rotavac-5C
Others
Rotavirus Infections Drug Segment by Application

Clinic
Hospital
Others
Rotavirus Infections Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

92 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Rotavirus Infections Drug Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Rotavirus Infections Drug Sales Estimates and Forecasts (2020-2031)
1.3 Rotavirus Infections Drug Market by Type
1.3.1 UMN-2001
1.3.2 RV-625
1.3.3 RV-3BB
1.3.4 Rotavac-5C
1.3.5 Others
1.4 Global Rotavirus Infections Drug Market Size by Type
1.4.1 Global Rotavirus Infections Drug Market Size Overview by Type (2020-2031)
1.4.2 Global Rotavirus Infections Drug Historic Market Size Review by Type (2020-2025)
1.4.3 Global Rotavirus Infections Drug Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Rotavirus Infections Drug Sales Breakdown by Type (2020-2025)
1.5.2 Europe Rotavirus Infections Drug Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Rotavirus Infections Drug Sales Breakdown by Type (2020-2025)
1.5.4 South America Rotavirus Infections Drug Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Rotavirus Infections Drug Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Rotavirus Infections Drug Industry Trends
2.2 Rotavirus Infections Drug Industry Drivers
2.3 Rotavirus Infections Drug Industry Opportunities and Challenges
2.4 Rotavirus Infections Drug Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Rotavirus Infections Drug Revenue (2020-2025)
3.2 Global Top Players by Rotavirus Infections Drug Sales (2020-2025)
3.3 Global Top Players by Rotavirus Infections Drug Price (2020-2025)
3.4 Global Rotavirus Infections Drug Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Rotavirus Infections Drug Major Company Production Sites & Headquarters
3.6 Global Rotavirus Infections Drug Company, Product Type & Application
3.7 Global Rotavirus Infections Drug Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Rotavirus Infections Drug Market CR5 and HHI
3.8.2 Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2024
3.8.3 2023 Rotavirus Infections Drug Tier 1, Tier 2, and Tier 3
4 Rotavirus Infections Drug Regional Status and Outlook
4.1 Global Rotavirus Infections Drug Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Rotavirus Infections Drug Historic Market Size by Region
4.2.1 Global Rotavirus Infections Drug Sales in Volume by Region (2020-2025)
4.2.2 Global Rotavirus Infections Drug Sales in Value by Region (2020-2025)
4.2.3 Global Rotavirus Infections Drug Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Rotavirus Infections Drug Forecasted Market Size by Region
4.3.1 Global Rotavirus Infections Drug Sales in Volume by Region (2026-2031)
4.3.2 Global Rotavirus Infections Drug Sales in Value by Region (2026-2031)
4.3.3 Global Rotavirus Infections Drug Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Rotavirus Infections Drug by Application
5.1 Rotavirus Infections Drug Market by Application
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Others
5.2 Global Rotavirus Infections Drug Market Size by Application
5.2.1 Global Rotavirus Infections Drug Market Size Overview by Application (2020-2031)
5.2.2 Global Rotavirus Infections Drug Historic Market Size Review by Application (2020-2025)
5.2.3 Global Rotavirus Infections Drug Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Rotavirus Infections Drug Sales Breakdown by Application (2020-2025)
5.3.2 Europe Rotavirus Infections Drug Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Rotavirus Infections Drug Sales Breakdown by Application (2020-2025)
5.3.4 South America Rotavirus Infections Drug Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Rotavirus Infections Drug Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Wuhan Institute of Biological Products Co Ltd
6.1.1 Wuhan Institute of Biological Products Co Ltd Comapny Information
6.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
6.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
6.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
6.2 Beijing Minhai Biotechnology Co Ltd
6.2.1 Beijing Minhai Biotechnology Co Ltd Comapny Information
6.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
6.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
6.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
6.3 UMN Pharma Inc
6.3.1 UMN Pharma Inc Comapny Information
6.3.2 UMN Pharma Inc Business Overview
6.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
6.3.5 UMN Pharma Inc Recent Developments
6.4 Serum Institute of India Ltd
6.4.1 Serum Institute of India Ltd Comapny Information
6.4.2 Serum Institute of India Ltd Business Overview
6.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
6.4.5 Serum Institute of India Ltd Recent Developments
6.5 Nanotherapeutics Inc
6.5.1 Nanotherapeutics Inc Comapny Information
6.5.2 Nanotherapeutics Inc Business Overview
6.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
6.5.5 Nanotherapeutics Inc Recent Developments
6.6 Medicago Inc
6.6.1 Medicago Inc Comapny Information
6.6.2 Medicago Inc Business Overview
6.6.3 Medicago Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
6.6.5 Medicago Inc Recent Developments
6.7 Curevac AG
6.7.1 Curevac AG Comapny Information
6.7.2 Curevac AG Business Overview
6.7.3 Curevac AG Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
6.7.5 Curevac AG Recent Developments
6.8 Biological E Ltd
6.8.1 Biological E Ltd Comapny Information
6.8.2 Biological E Ltd Business Overview
6.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
6.8.5 Biological E Ltd Recent Developments
6.9 Bharat Biotech International Ltd
6.9.1 Bharat Biotech International Ltd Comapny Information
6.9.2 Bharat Biotech International Ltd Business Overview
6.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
6.9.5 Bharat Biotech International Ltd Recent Developments
7 North America by Country
7.1 North America Rotavirus Infections Drug Sales by Country
7.1.1 North America Rotavirus Infections Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Rotavirus Infections Drug Sales by Country (2020-2025)
7.1.3 North America Rotavirus Infections Drug Sales Forecast by Country (2026-2031)
7.2 North America Rotavirus Infections Drug Market Size by Country
7.2.1 North America Rotavirus Infections Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Rotavirus Infections Drug Market Size by Country (2020-2025)
7.2.3 North America Rotavirus Infections Drug Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Rotavirus Infections Drug Sales by Country
8.1.1 Europe Rotavirus Infections Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Rotavirus Infections Drug Sales by Country (2020-2025)
8.1.3 Europe Rotavirus Infections Drug Sales Forecast by Country (2026-2031)
8.2 Europe Rotavirus Infections Drug Market Size by Country
8.2.1 Europe Rotavirus Infections Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Rotavirus Infections Drug Market Size by Country (2020-2025)
8.2.3 Europe Rotavirus Infections Drug Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Rotavirus Infections Drug Sales by Country
9.1.1 Asia-Pacific Rotavirus Infections Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Rotavirus Infections Drug Sales by Country (2020-2025)
9.1.3 Asia-Pacific Rotavirus Infections Drug Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Rotavirus Infections Drug Market Size by Country
9.2.1 Asia-Pacific Rotavirus Infections Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Rotavirus Infections Drug Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Rotavirus Infections Drug Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Rotavirus Infections Drug Sales by Country
10.1.1 South America Rotavirus Infections Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Rotavirus Infections Drug Sales by Country (2020-2025)
10.1.3 South America Rotavirus Infections Drug Sales Forecast by Country (2026-2031)
10.2 South America Rotavirus Infections Drug Market Size by Country
10.2.1 South America Rotavirus Infections Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Rotavirus Infections Drug Market Size by Country (2020-2025)
10.2.3 South America Rotavirus Infections Drug Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Rotavirus Infections Drug Sales by Country
11.1.1 Middle East and Africa Rotavirus Infections Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Rotavirus Infections Drug Sales by Country (2020-2025)
11.1.3 Middle East and Africa Rotavirus Infections Drug Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Rotavirus Infections Drug Market Size by Country
11.2.1 Middle East and Africa Rotavirus Infections Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Rotavirus Infections Drug Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Rotavirus Infections Drug Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Rotavirus Infections Drug Value Chain Analysis
12.1.1 Rotavirus Infections Drug Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Rotavirus Infections Drug Production Mode & Process
12.2 Rotavirus Infections Drug Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Rotavirus Infections Drug Distributors
12.2.3 Rotavirus Infections Drug Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.